Day: July 29, 2021

Company Announcement No. 901 The Board of Directors of DSV Panalpina A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 15 March 2021. The authority is valid until 15 March 2026 and covers a maximum of 22,400,000 shares. Purpose The purpose of the share buyback is to adjust the capital structure and meet obligations relating to the Group’s share-based incentive programmes. At the Annual General Meeting of DSV Panalpina A/S, a resolution will be proposed that any shares not used for hedging or the incentive programmes will be cancelled. Time frame The share buyback programme will run from 29 July 2021 to 25 October 2021 at the latest, both days inclusive. During this period, DSV Panalpina A/S will buy its own shares up to maximum of DKK 4,000 million in accordance with Regulation No. 596/2014...

RELEASE OF THE HALF YEAR 2021 RESULTS PRESENTATION The Group has released its half year 2021 results presentation on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2021/07/20210729-H1-2021-Results-Presentation.pdf  ANALYST AND INVESTOR CONTACTS Lionel Benchimol – +33 (0)1 53 65 64 17lbenchimol@groupe-casino.fr or +33 (0)1 53 65 24 17IR_Casino@groupe-casino.fr PRESS CONTACTS Casino Group – Communications DepartmentStéphanie Abadie – sabadie@groupe-casino.fr – +33 (0)6 26 27 37 05 or +33 (0)1 53 65 24 78 – directiondelacommunication@groupe-casino.fr Agence IMAGE 7Karine Allouis – +33 (0)1 53 70 74 84 – kallouis@image7.frFranck Pasquier – +33 (0)6 73 62 57 99 – fpasquier@image7.fr   Disclaimer   This press release was prepared solely for information purposes, and should not be construed...

PRESS RELEASE Strong revenue growth in 3rd quarter ended 30 June 2021Triple-digit growth of B2C refurbished used cars salesGroup revenue1 growth of 68% in 3rd quarter ended 30 June 2021 to €377.5 million on a combined2 basis (+32% over the first nine months of the fiscal year). 68% increase in volumes with 23,197 B2C vehicles sold during the quarter, including 14,346 B2C refurbished used cars 116% growth in revenues from sales of B2C refurbished used cars in Q3 (and +48% over the first nine months on a combined basis) Very strong performance in all countries where the Group operates Integration of CarSupermarket in the United Kingdom well on track with already visible achievements Successful IPO on Euronext Paris in June providing the Group with significant firepower to fuel its pan European expansion and accelerate its growth Confirmation...

NOMINATION OF CHIEF FINANCIAL OFFICER Amsterdam, the Netherlands – Flow Traders N.V. (Euronext: FLOW) announces that the Supervisory Board has nominated Mike Kuehnel for appointment as Chief Financial Officer and member of the Management Board. Given Flow Traders’ ambitions and strategic growth agenda, the Supervisory Board has taken the decision to expand the Management Board from four to five members with the nomination of Mike Kuehnel for appointment as Chief Financial Officer. Through this new, dedicated Chief Financial Officer function, Mike will help to further shape Flow Traders’ strategy, develop organic and non-organic growth initiatives as well as intensify communications with key stakeholders. Mike Kuehnel will join Flow Traders on 1 August 2021 and all regulatory approvals have been received. Prior to joining Flow Traders,...

29 July 2021, 07:30 CET ArcelorMittal (the ‘Company’) today announces a new share buyback program in the amount of $2.2 billion (the ‘Program’) under the authorization given by the annual general meeting of shareholders held on 8 June 2021 (the ‘AGM Authorization’). For the background to this Program, reference is made to the Company’s second quarter and half year 2021 results press release dated 29 July 2021 which outlines that it will (i) return the proceeds from the redeemed Cleveland Cliffs preference shares and (ii) advance a part of its prospective 2022 capital return to shareholders (to be funded from 2021 surplus cash flow under the capital return policy announced in February 2021) by launching a new $2.2 billion share buyback. This Program will be completed by 31 December 2021, subject to market conditions. The shares acquired...

Paris, July 29, 2021 Sales growth accelerated – Full-year guidance raised Q2 2021 sales grew double digit to €8.7 billion (up 12.4% at CER) mainly driven by Dupixent® and VaccinesSpecialty Care sales increased 22.0%, due to strong Dupixent® (+56.6%) and new oncology Vaccines up 16.2%, driven by meningitis and boosters franchise recovery; accelerating the mRNA pipeline General Medicines sales increased 4.2% supported by core assets (up 11.8%) including COVID related demand for Lovenox® CHC increased 11.9% due to growth of Digestive Wellness category largely offsetting low demand for cough and cold brandsQ2 2021 business EPS(1) growth of 16.4% at CER driven by sales performance and efficienciesBusiness EPS(1) was €1.38, up 7.8% on a reported basis In H1 2021, cost savings of €450 million were realized of which the vast majority...

H1 2021 resultsAdjusted revenue up +0.6% to €1,082.3 million Adjusted organic revenue up +2.9%, with Q2 at +80.2% Adjusted operating margin of €31.4 million, +€93.2 million yoy Adjusted EBIT, before impairment, of -€166.9 million, +€91.6 million yoy Net income Group share of -€161.3 million, +€93.7 million yoy Adjusted free cash flow of -€63.2 million Third quarter 2021 adjusted organic revenue growth above +20%Paris, July 29th, 2021 – JCDecaux SA (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announced today its 2021 half-year financial results. Commenting on the 2021 first half-year results, Jean-François Decaux, Chairman of the Executive Board and Co-CEO of JCDecaux, said: “Our H1 2021 group revenue reached €1,082.3 million, a +0.6% yoy revenue growth or +2.9% on an organic basis driven by...

Company Announcement No. 900 Selected key figures and ratios for the period 1 January – 30 June 2021(DKKm) Q2 2021 Q2 2020 YTD 2021 YTD 2020         Key figures and ratios        Revenue 37,831 28,782 71,447 56,091Gross profit 8,333 7,386 16,118 14,070Operating profit (EBIT) before special items 3,571 2,613 6,638 4,179Profit after tax 2,527 1,390 4,856 1,721         Adjusted earnings for the period 2,580 1,838 4,970 2,593Adjusted free cash flow     2,817 3,356Conversion ratio 42.9% 35.4% 41.2% 29.7%Diluted adjusted earnings per share of DKK 1 for the last 12 months     37.1 20.8Jens Bjørn Andersen, Group CEO: “We are proud to report strong results for the first six months of 2021, where we deliver an EBIT result equivalent to our full-year EBIT of 2019. This is a clear testament to the successful...

PRESS RELEASE: Amsterdam – 29 July 2021. Intertrust N.V. (“Intertrust” or “Company”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in the international business environment, today publishes its results for the second quarter and half year ended 30 June 2021. Q2 2021 HighlightsUnderlying revenue up 4.8% year-on-year to EUR 143.4 million, primarily driven by a strong performance in Funds Healthy pipeline due to greater ability to cross sell between service lines, upsell to existing customers as well as larger order ticket sizes Adjusted EBITA of EUR 39.9 million (Q2 2020: EUR 44.4 million) including one-off costs of EUR 6.4 million, mainly related to the CIMA fine and other legal and compliance costs Adjusted EBITA margin of 27.8% (Q2 2020: 31.9%) reflecting...

Basel, Switzerland, July 29, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea’s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer.1 Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity. Dr. Marc Engelhardt, Chief Medical Officer, commented: “The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted...